NeoStem (Amex: NBS) Public Offering of Common Stock
July 19th, 2011
No comments
NYSE-Amex: NBS to sell shares of its common stock and warrants in a public offering. Read more…
Archive
Posts Tagged ‘NBS’
$19M Concurrent Offerings, NeoStem (Amex: NBS)
November 16th, 2010
No comments
NBS announced concurrently a 6.337M common stock offering with a warrant at $1.45 and a registered direct offering of 10,582,011 preferred units. Read more…
Categories: AMEX: NBS, financings, NeoStem, Registered Direct Offering, Stem Cell Technology
Q3/10 Results, NeoStem (AMEX: NBS)
November 12th, 2010
No comments
NBS reported a net loss of $7.14M or ($0.13) per share. Read more…
Categories: AMEX: NBS, NYSE Amex: NBS, Q3/10 Results, Stem Cell Technology
Orthopedic Stem Cell Treatment Approval in China, NeoStem (NBS)
November 4th, 2010
No comments
NBS’ single side and bilateral arthroscopic orthopedic autologous adult stem cell based treatment was approved Read more…
Categories: AMEX: NBS, Stem Cell Technology
Merger Agreement, Progenitor Cell Therapy and NeoStem (NYSE Amex: NBS)
September 23rd, 2010
No comments
NeoStem and Progenitor Cell Therapy (PCT) a privately held cell therapy company in NJ and Cal on 9/23/10 signed of a definitive merger agreement whereby NBS will acquire Progenitor Cell Therapy. Read more…
Categories: Merger Agreement, Stem Cell Technology
Q2/10 Results, NeoStem (Amex:NBS)
August 16th, 2010
No comments
Net loss to shareholders was $5.42 M and $0.11 per diluted loss per share.
Categories: Quarterly Earnings, Stem Cell Technology
New Retinal Disease Collaboration, NeoStem (NBS)
August 11th, 2010
No comments
NBS has entered into a sponsored research agreement (SRA) with the Schepens Eye Research Institute, Read more…
Categories: New Collaboration, Stem Cell Technology
US Army Grant for Traumatic Wounds, NeoStem (NYSE Amex)
August 1st, 2010
No comments
NBS has been awarded a $700 K contract for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing Read more…
Categories: Stem Cell Technology, US Army Grant for Traumatic Wounds
NeoStem (NBS) Shareholder Equity Increases by $13.7 M
May 21st, 2010
No comments
NBS announced (5/20/10) the conversion of Convertible Redeemable Series C Preferred Stock (Series C Preferred) by RimAsia Capital Partners, LP (“RimAsia”), a principal shareholder. With the conversion of the Series C Preferred, NBS will no longer be required to pay the annual dividend and expects to recognize cash savings of $409 K per year. Read more…
Categories: financings, Stem Cell Technology
Vatican’s Pontifical Council and NeoStem (NBS) in Educational Partnership
May 20th, 2010
No comments
NBS and the Vatican’s Pontifical Council for Culture announced a joint initiative that includes their charitable organizations to expand research and raise awareness of adult stem cell therapies. Read more…
Categories: Stem Cell Technology
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.